£25m Antibiotic Resistance Research Facility Opens in 2017
Liverpool’s future as a world class life science hub has taken a huge step forward with the announcement of a new £25m laboratory development that will enable innovative research into antibiotic resistance.
The new Liverpool Life Sciences Accelerator, co-locates the Royal Liverpool and Broadgreen University Hospitals NHS Trust, the Liverpool School of Tropical Medicine (LSTM) and a raft of relevant SMEs with larger scale industrial collaboration through pre-existing product development partnerships. The 70,000 square foot building will provide state-of-the-art laboratory space and offices.
The Chrysalis Fund has committed an £11.5m loan for the development of Accelerator. The fund, which supports commercial regeneration activities across the Liverpool city region, has now invested more than £32m into a number of projects.
Situated on Daulby Street, within the grounds of the Royal Liverpool University Hospital, the Accelerator will have five floors. Two floors will be available for commercial laboratories and office facilities for Small & Medium-sized Enterprises involved in developing products that will improve patient care and treatment outcomes. A further two floors will be devoted to LSTM’s Resistance mitigation portfolio, which is playing a leading role in the global fight against the growing threat of antibiotic resistance.
Helen Jackson, director of strategy and transformation at the Trust, said: “The Accelerator will provide a hub for life sciences, enabling clinicians, academics and industry to collaborate in research and innovation to develop their ideas into the very latest life-saving treatments.
“The Accelerator is the first development in the creation of a city centre health campus that will be built on the site of the existing Royal Liverpool University Hospital. This Liverpool Health Campus will consist of 200,000 square feet of space, attracting life sciences, biomedical research companies and health organisations. This will generate 5,000 high value jobs and help the city develop a thriving life science economy.”
Building on site will start in mid-November, with the Life Sciences Accelerator due to open in June 2017.
Tags: Antibiotic Resistance
Date Published: November 10, 2015
Source article link: Royal Liverpool and Broadgreen University Hospitals NHS Trust
BIVDA Calls for Funding to Implement Rapid Diagnostics
Study Outlines ‘Perfect Storm’ that Led to Antibiotic Resistance Epidemic
Selective Growth of Colistin Resistant Bacteria on CHROMagar™ COL-APSE
New Multiplex Real-time PCR Kits Detect Clinically Relevant β-lactamase Genes
FDA-Cleared Liofilchem MIC Test Strip (MTS™) Clindamycin (CD)